In the next phase of our research, we plan to verify whether glycitein can enhance the activity of UBB to counteract tumor vasculature and synergize with pazopanib, thereby increasing its sensitivity, thus developing potential therapeutic agents against pazopanib resistance. The gene discussed is UBB; the disease is neoplasm.